Onglyza (saxagliptin) is an oral DPP-4 inhibitor approved by the FDA in 2009 for type 2 diabetes. It lowers A1C by 0.5 to 0.8 percent depending on dose, has no effect on weight, and carries low hypoglycemia risk when used alone. The defining feature in its risk-benefit profile is the SAVOR-TIMI 53 trial, which showed a 27 percent increase in heart failure hospitalizations — leading most clinicians to avoid Onglyza in patients with heart failure or high heart failure risk. Once-daily dosing, simple titration, and useful combination products (Kombiglyze XR, Qtern) keep it in use for selected patients.
What Onglyza Is
- Generic name: saxagliptin
- Drug class: DPP-4 inhibitor (gliptins)
- Manufacturer: AstraZeneca
- FDA approval: July 2009
- Forms: 2.5 mg and 5 mg tablets, once daily
- Combinations: Kombiglyze XR (with metformin extended release), Qtern (with dapagliflozin)
How Onglyza Works
Onglyza inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down the incretin hormones GLP-1 and GIP. Blocking DPP-4 raises endogenous incretin levels, which:
- Stimulate glucose-dependent insulin secretion from pancreatic beta cells
- Suppress glucagon secretion from alpha cells
- Slow gastric emptying very modestly
- Produce minimal direct effect on appetite or body weight
Because the action is glucose dependent, hypoglycemia risk is low when used alone.
Approved Use
Onglyza is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It can be used:
- As monotherapy (less common — usually for users intolerant of metformin)
- Combined with metformin, sulfonylureas, thiazolidinediones, or insulin
- As part of Kombiglyze XR (with metformin) or Qtern (with dapagliflozin)
It is not approved for type 1 diabetes or DKA.
Dosing
| Setting | Dose | Notes |
|---|---|---|
| Standard adult | 5 mg once daily | With or without food |
| eGFR ≥ 45 | 5 mg once daily | No adjustment |
| eGFR < 45 | 2.5 mg once daily | Including dialysis |
| Strong CYP3A4/5 inhibitor | 2.5 mg once daily | Ketoconazole, clarithromycin, ritonavir |
| Hepatic impairment | No adjustment | Use caution in severe disease |
SAVOR-TIMI 53 — What the Trial Showed
SAVOR-TIMI 53 (Scirica et al., NEJM 2013) enrolled 16,492 patients with type 2 diabetes plus cardiovascular disease or multiple risk factors. Results:
- Primary endpoint (3-point MACE): non-inferior to placebo (HR 1.00), neither benefit nor harm
- Heart failure hospitalization: significantly increased (HR 1.27, p=0.007)
- All-cause mortality: no significant difference
- Acute pancreatitis: small numerical increase, not statistically significant
- Hypoglycemia: increased (HR 1.22) — driven mostly by users also on sulfonylureas or insulin
The heart failure signal led the FDA to add a warning to the label in April 2016. Several other DPP-4 inhibitors (sitagliptin and linagliptin) did not show this signal in their respective trials, so most clinicians switch to those agents when heart failure risk is present.
Benefits
- A1C reduction of 0.5 to 0.8 percent depending on dose and baseline
- Weight neutral — no gain or loss
- Low hypoglycemia risk on monotherapy
- Once-daily oral dosing
- Well tolerated in most users
- No need for dose titration (only the two options)
- Useful in moderate CKD with dose reduction
Common Side Effects
| Side Effect | Approximate Frequency |
|---|---|
| Upper respiratory tract infection | 7–8% |
| Headache | 7% |
| Urinary tract infection | 6% |
| Nasopharyngitis | 4–5% |
| Sinusitis | 3% |
| Diarrhea or constipation | 2–3% |
| Peripheral edema | ~3% (higher with TZD) |
Rare but Serious Side Effects
- Heart failure hospitalization — 27 percent increase in SAVOR-TIMI 53; avoid in heart failure
- Acute pancreatitis — class signal; stop if severe abdominal pain radiating to the back
- Severe joint pain — FDA class warning issued in 2015; usually resolves on stopping
- Bullous pemphigoid — rare blistering autoimmune skin reaction; requires stopping and dermatology evaluation
- Hypersensitivity — urticaria, facial edema, anaphylaxis (very rare)
- Acute kidney injury — rare; usually with volume depletion
Drug Interactions
- Strong CYP3A4/5 inhibitors raise saxagliptin levels — reduce dose to 2.5 mg
- Examples: ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir, nelfinavir
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce effect
- Combination with sulfonylureas or insulin raises hypoglycemia risk — consider reducing those doses
Who Should Avoid Onglyza
- Heart failure (especially HFrEF) or high heart failure risk
- Prior pancreatitis (relative contraindication, class-wide)
- Type 1 diabetes
- DKA
- Pregnancy or breastfeeding
- Known hypersensitivity to DPP-4 inhibitors
Onglyza Combinations
| Brand | Components | Dosing |
|---|---|---|
| Onglyza | Saxagliptin 2.5 or 5 mg | Once daily |
| Kombiglyze XR | Saxagliptin + metformin ER | Once daily with evening meal |
| Qtern | Saxagliptin + dapagliflozin | Once daily morning |
How Onglyza Compares With Other DPP-4 Inhibitors
| Drug | HF Signal | Renal Dose Adjust | Once-Daily |
|---|---|---|---|
| Onglyza (saxagliptin) | Yes (SAVOR) | Yes | Yes |
| Januvia (sitagliptin) | No (TECOS) | Yes | Yes |
| Tradjenta (linagliptin) | No (CARMELINA) | No | Yes |
| Nesina (alogliptin) | Yes (EXAMINE) | Yes | Yes |
Monitoring on Onglyza
- A1C every 3 months until stable, then every 6 months
- eGFR at baseline and every 6 to 12 months
- Symptoms of heart failure (dyspnea, swelling, weight gain) — report promptly
- Joint symptoms — ask about new joint pain
- Skin — look for blistering or severe rash
- Abdominal pain — evaluate promptly
Practical Notes for Users
- Take at the same time each day, with or without food
- If a dose is missed and the next dose is more than 12 hours away, take it; otherwise skip
- Tell every prescriber and dentist you are on saxagliptin before they start new medication
- Report new shortness of breath, rapid weight gain, or ankle swelling early
- Stop and seek evaluation for severe abdominal pain radiating to the back
- Stop and call your clinician for new severe joint pain
Related Reading
For the broader class see our DPP-4 inhibitors list and Onglyza side effects guide. Compare with other DPP-4 agents at Tradjenta (linagliptin) and Nesina (alogliptin). For broader context see our treatment overview and A1C levels. External: the SAVOR-TIMI 53 trial and the ADA Standards of Care.
The Bottom Line
Onglyza (saxagliptin) is a once-daily oral DPP-4 inhibitor that lowers A1C by 0.5 to 0.8 percent with weight neutrality and low hypoglycemia risk. The defining concern is the 27 percent increase in heart failure hospitalizations seen in SAVOR-TIMI 53, which led to an FDA heart failure warning and shifts many clinicians toward sitagliptin or linagliptin in users with heart failure or high heart failure risk. For patients without heart failure concerns who tolerate it well, Onglyza is a reasonable, simple, well-tolerated agent — particularly in combinations like Kombiglyze XR with metformin or Qtern with dapagliflozin.
